Asthma  >>  Riarify (beclometasone/formoterol/glycopyrrolate)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
TRIMARAN, NCT02676076 / 2015-000716-18: TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Completed
3
1153
Europe
CHF 5993 100/6/12.5 µg, CHF 1535 100/6 µg
Chiesi Farmaceutici S.p.A.
Asthma
05/18
05/18
TRIGGER, NCT02676089 / 2015-000717-40: TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium

Completed
3
1433
Europe, RoW
CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Chiesi Farmaceutici S.p.A.
Asthma
05/18
05/18
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)

Recruiting
3
790
Europe
CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant
Chiesi Farmaceutici S.p.A.
Asthma
08/24
09/25

Download Options